Janux Therapeutics (NASDAQ:JANX) Receives Outperform Rating from William Blair

William Blair reiterated their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report released on Thursday,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

Other equities analysts have also recently issued reports about the stock. UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research report on Thursday, November 7th. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 price target for the company. Scotiabank lowered their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Finally, Wedbush reiterated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.44.

Janux Therapeutics Trading Down 4.2 %

Shares of Janux Therapeutics stock traded down $2.16 during trading on Thursday, reaching $48.94. The company’s stock had a trading volume of 258,092 shares, compared to its average volume of 709,310. Janux Therapeutics has a fifty-two week low of $7.79 and a fifty-two week high of $65.60. The firm has a market cap of $2.57 billion, a PE ratio of -43.67 and a beta of 3.52. The company has a 50-day moving average price of $49.61 and a two-hundred day moving average price of $46.50.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, analysts predict that Janux Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the completion of the transaction, the chief executive officer now directly owns 307,054 shares in the company, valued at approximately $14,219,670.74. This represents a 7.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $42.33, for a total transaction of $92,364.06. Following the sale, the insider now directly owns 7,000 shares of the company’s stock, valued at $296,310. The trade was a 23.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 420,610 shares of company stock valued at $19,288,666 over the last quarter. Company insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in JANX. Summit Securities Group LLC acquired a new position in shares of Janux Therapeutics in the 2nd quarter worth approximately $29,000. Amalgamated Bank boosted its holdings in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd acquired a new position in Janux Therapeutics in the second quarter worth $42,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Janux Therapeutics during the second quarter worth $151,000. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.